肌球蛋白轻链激酶在恶性肿瘤中的研究进展  

Research progress on myosin light chain kinase in malignant tumors

作　　者：杨哲宇 肖瑞[2] 王瑞[1] 任建军[1] Yang Zheyu;Xiao Rui;Wang Rui;Ren Jianjun(Department of Hepatobiliary Surgery,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;Key Laboratory of Molecular Pathology,Inner Mongolia Medical University,Hohhot 010050,China)

机构地区：[1]内蒙古医科大学附属医院肝胆外科,呼和浩特010050 [2]内蒙古医科大学分子病理学重点实验室,呼和浩特010050

出　　处：《中国医药》2024年第11期1756-1760,共5页China Medicine

基　　金：内蒙古自治区自然科学基金(2022MS08049);内蒙古自治区科技计划(2022YFSH0098);内蒙古自治区高等学校科学研究项目(NJZZ22685);内蒙古医科大学面上项目(YKD2021MS024)。

摘　　要：近年来,肌球蛋白轻链激酶(MLCK)作为细胞骨架和细胞运动的重要调节因子,在多种肿瘤的发生发展中发挥着关键作用。MLCK通过细胞信号转导,参与调控肿瘤细胞的增殖、迁移、侵袭和凋亡等生物过程。鉴于MLCK在肿瘤发展中的关键作用,其作为肿瘤治疗的潜在靶点被广泛研究,旨在开发针对MLCK的治疗策略,以提高治疗效率和患者生存质量。本文综述了MLCK在不同类型肿瘤中的表达模式、功能机制及其潜在的临床应用价值,同时探讨了MLCK作为潜在治疗靶点的研究现状及未来发展方向,为临床治疗提供新的思路和策略。In recent years,myosin light chain kinase(MLCK)has played a crucial role as an important regulator of the cytoskeleton and cell movement in various types of tumors.MLCK participates in regulating various biological processes,such as cell proliferation,migration,invasion,and apoptosis,through cell signal transduction in tumor development.Given the crucial role of MLCK in tumor development,it has been extensively studied as a potential therapeutic target,with the aim of developing therapeutic strategies to improve treatment efficacy and patient quality of life.This review summarizes the expression patterns,functional mechanisms,and potential clinical application value of MLCK in different types of tumors,and discusses the current status and future directions of MLCK as a potential therapeutic target,providing new ideas and strategies for clinical treatment.

关 键 词：肿瘤 肌球蛋白轻链激酶 细胞迁移 细胞骨架 治疗靶点 

分 类 号：R473.73[医药卫生—护理学]